What are the diagnostic criteria for Guillain-Barré Syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Criteria for Guillain-Barré Syndrome

The diagnosis of Guillain-Barré syndrome requires progressive bilateral weakness of the limbs with absent or decreased tendon reflexes, supported by cerebrospinal fluid analysis showing elevated protein with normal cell count and electrodiagnostic studies demonstrating peripheral nerve dysfunction. 1

Required Features for Diagnosis

The two essential criteria that must be present are: 1

  • Progressive bilateral weakness of arms and legs (initially only legs may be involved)
  • Absent or decreased tendon reflexes in affected limbs at some point during the clinical course

Features That Strongly Support the Diagnosis

These findings significantly increase diagnostic certainty when present alongside the required features: 1

  • Progressive phase lasting days to 4 weeks (usually <2 weeks) 1
  • Relative symmetry of symptoms and signs 1
  • Mild sensory symptoms and signs (absent in pure motor variant) 1
  • Cranial nerve involvement, especially bilateral facial palsy 1
  • Autonomic dysfunction including blood pressure/heart rate instability 1, 2
  • Muscular or radicular back or limb pain 1, 2
  • Increased CSF protein with normal cell count (albumino-cytological dissociation) - though normal protein levels do not rule out diagnosis, particularly in the first week when 30-50% may have normal CSF 1, 3, 2
  • Electrodiagnostic features of motor or sensorimotor neuropathy - normal electrophysiology early in disease does not exclude GBS 1, 3

Features That Cast Doubt on the Diagnosis

These findings should prompt consideration of alternative diagnoses: 1

  • Elevated CSF cell count (>50 × 10⁶/L mononuclear or polymorphonuclear cells) 1
  • Marked, persistent asymmetry of weakness 1
  • Bladder or bowel dysfunction at onset or persistent during disease course 1
  • Severe respiratory dysfunction with limited limb weakness at onset 1
  • Sensory signs with limited weakness at onset 1
  • Fever at onset 1
  • Nadir reached in <24 hours 1
  • Sharp sensory level indicating spinal cord injury 1
  • Hyper-reflexia, clonus, or extensor plantar responses 1
  • Continued progression >4 weeks after symptom onset 1
  • Altered consciousness (except in Bickerstaff brainstem encephalitis variant) 1

Diagnostic Approach Algorithm

Step 1: Clinical History - Look for antecedent infection (diarrhea or respiratory illness) within 1-4 weeks before symptom onset 2, 4

Step 2: Neurological Examination - Document ascending bilateral symmetric weakness pattern (legs → arms → cranial nerves), assess reflexes in all limbs, test for sensory deficits, examine cranial nerves particularly for bilateral facial weakness, and check for autonomic signs 1, 2

Step 3: CSF Analysis - Perform lumbar puncture to demonstrate albumino-cytological dissociation (elevated protein with normal cell count <50 × 10⁶/L), though this may be absent in the first week 1, 3, 4

Step 4: Electrodiagnostic Studies - Conduct nerve conduction studies to demonstrate peripheral nerve dysfunction and classify subtypes (AIDP, AMAN, AMSAN), recognizing that studies may be normal early in disease and should be repeated 3-8 weeks after onset if initially equivocal 1, 3, 4

Step 5: Respiratory Assessment - Measure vital capacity and negative inspiratory force as respiratory failure can occur rapidly without obvious dyspnea in 20% of patients 2, 4

Important Clinical Variants

The diagnosis must account for several recognized variants that may not meet all typical criteria: 1

  • Pure motor variant (5-70% of cases) - motor weakness without sensory signs 1
  • Miller Fisher syndrome (5-25% of cases) - ophthalmoplegia, ataxia, and areflexia 1, 2
  • Paraparetic variant (5-10% of cases) - weakness restricted to legs 1
  • Pharyngeal-cervical-brachial variant (<5% of cases) - weakness of pharyngeal, cervical and brachial muscles without lower limb involvement 1

Critical Diagnostic Pitfalls

Timing of investigations matters: CSF protein may be normal in 30-50% of patients during the first week, and electrodiagnostic studies can be normal early in the disease course 3, 4. Do not exclude GBS based on normal early investigations.

Reflexes can be preserved initially: Approximately 10% of patients have normal or brisk deep tendon reflexes at presentation, though almost all develop areflexia at nadir 2. Early preserved reflexes do not exclude the diagnosis.

Children present atypically: Pediatric patients may present with pain, refusal to walk, or abnormal gait rather than classic ascending weakness, and GBS is correctly diagnosed at admission in only one-third of preschool-aged children 1.

Consider A-CIDP: If progression continues beyond 8 weeks from onset, change the diagnosis to acute-onset chronic inflammatory demyelinating polyradiculoneuropathy, which occurs in approximately 5% of patients initially diagnosed with GBS 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Guillain-Barré Syndrome Diagnosis and Clinical Features

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Electrophysiological Differentiation of Guillain-Barré Syndrome and Critical Illness Myopathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the diagnosis, treatment, and prognosis of Guillain Barre (Guillain-Barré) syndrome?
What is the most likely diagnosis for a patient with ascending muscle weakness, areflexia, and sensory involvement following a URTI?
What is the diagnosis and treatment for an acute demyelinating process progressing from peripheral to proximal?
What is the initial therapy for a patient with ascending bilateral lower extremity weakness following an upper respiratory illness, suggestive of Guillain-Barré Syndrome (GBS)?
Can Guillain-Barré Syndrome (GBS) cause irreversible damage and what is the timeline for potential damage?
What would be the best approach for managing anxiety and sleep in an elderly patient taking alprazolam (Xanax) 0.5mg, who has recently experienced a dosage increase from 0.25mg, and has been inconsistent with escitalopram (Lexapro), given her relative's terminal illness and concerns about long-term benzodiazepine use?
What is the recommended dosage of Motrin (ibuprofen) for an elderly patient?
Is Metronidazole safe in patients with Autoimmune Hemolytic Anemia (AIHA)?
What measures can be taken to prevent bacterial infections, such as streptococcal (strep) infections and sinus infections, in a child who has a history of perianal strep and sinus infections, and is currently using Flonase (fluticasone) and Claritin (loratadine)?
How is hypomagnesemia (low magnesium levels) treated?
What are the next steps for managing new onset mid bicep pain 3 weeks after rotator cuff repair?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.